
WHAT IS CLAIMED IS

1. A solid form comprising a hydrochloride salt of 3-(5-amino-2-methyl-4-oxo-4*H*-quinazolin-3-yl)-piperidine-2,6-dione:



~~or a stereoisomer thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, or clathrate thereof,~~ having an X-ray powder diffraction pattern comprising:

~~peaks at approximately 14.6 °2θ, 15.6 °2θ, 16.7 °2θ, 21.9 °2θ and 30.0 °2θ;~~

~~peaks at approximately 10.6 °2θ, 14.7 °2θ, 19.1 °2θ and 25.9 °2θ;~~

~~peaks at approximately 10.8 °2θ, 15.1 °2θ, 25.1 °2θ and 26.6 °2θ;~~

~~peaks at approximately 16.7 °2θ, 21.7 °2θ, 21.9 °2θ and 25.8 °2θ;~~

~~peaks at approximately 7.3 °2θ, 14.6 °2θ, 22.0 °2θ, 30.0 °2θ and 37.0 °2θ;~~

~~peaks at approximately 14.5 °2θ, 15.7 °2θ, 22.7 °2θ and 29.9 °2θ; or~~

peaks at approximately 8.6 °2θ, 13.1 °2θ, 20.5 °2θ and 26.3 °2θ.

~~2. The solid form of claim 1, which is a solid form of a hydrochloride salt of 3-(5-amino-2-methyl-4-oxo-4*H*-quinazolin-3-yl)-piperidine-2,6-dione and has an X-ray powder diffraction pattern comprising peaks at about 8.6, 13.1, 20.5 and 26.3 degrees 2θ.~~

~~3~~2. The solid form of claim ~~2~~1, having an X-ray powder diffraction pattern substantially as shown in FIG. 18.

~~4~~3. The solid form of claim ~~2~~1, having an X-ray powder diffraction pattern comprising peaks at about 8.6, 11.3, 13.1, 15.3, 17.3, 20.5, 22.7, 23.6, 26.3 and 31.4 degrees 2θ.

~~5~~4. The solid form of any one of claims ~~2-4~~1-3, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 276 °C.

~~6~~5. The solid form of any one of claims ~~2-5~~1-4, having a thermal gravimetric analysis plot comprising a mass loss of less than about 0.5% when heated from about 25 °C to about 150 °C.

~~7~~6. The solid form of any one of claims ~~2-6~~1-5, which is anhydrous.

~~8~~7. The solid form of any one of claims ~~2-7~~1-6, which exhibits a mass increase of less than about 0.5% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

~~9~~8. The solid form of any one of claims ~~2-8~~1-7, which is substantially nonhygroscopic.

~~10~~9. The solid form of any one of claims ~~2-9~~1-8, which is stable upon exposure to about 40 °C and about 75% relative humidity for about 4 weeks.

~~11~~10. The solid form of any one of claims ~~2-10~~1-9, wherein the molar ratio of 3-(5-amino-2-methyl-4-oxo-4*H*-quinazolin-3-yl)-piperidine-2,6-dione to hydrochloride is from about 0.1 to about 10.

~~12. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 1.~~

~~13. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 14.6, 15.6, 16.7, 21.9 and 30.0 degrees 2θ.~~

~~14. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 9.2, 13.4, 14.0, 14.6, 15.6, 16.7, 18.5, 21.9, 22.7, 24.8, 28.1, 30.0 and 37.0 degrees 2θ.~~

~~15. The solid form of any one of claims 12-14, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 282 °C.~~

~~16. The solid form of any one of claims 12-15, having a thermal gravimetric analysis plot comprising a mass loss of less than about 6% when heated from about 25 °C to about 150 °C.~~

~~17. The solid form of any one of claims 12-16, which exhibits a mass increase of less than or equal to about 6% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.~~

~~18. The solid form of any one of claims 12-17, which is hydrated.~~

~~19. The solid form of claim 18, which the crystal lattice of the solid form comprises about one molar equivalent of water per mole of 3-(5-amino-2-methyl-4-oxo-4*H*-quinazolin-3-yl)-piperidine-2,6-dione.~~

~~20. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 4.~~

~~21. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.6, 14.7, 19.1 and 25.9 degrees 2θ.~~

~~22. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.6, 11.4, 12.6, 13.7, 14.7, 19.1, 20.3, 20.9, 21.2, 22.9, 24.9, 25.3, 25.9, 26.9, 29.5 and 33.8 degrees 2θ.~~

~~23. The solid form of any one of claims 20-22, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 279 °C.~~

~~24. The solid form of any one of claims 20-23, having a thermal gravimetric analysis plot comprising a mass loss of less than about 0.1% when heated from about 25 °C to about 150 °C.~~

~~25. The solid form of any one of claims 20-24, which exhibits a mass increase of less than about 0.2% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.~~

~~26. The solid form of any one of claims 20-25, which is unsolvated.~~

~~27. The solid form of any one of claims 20-26, which is substantially nonhygroscopic.~~

~~28. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 7.~~

~~29. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.8, 15.1, 25.1 and 26.6 degrees 2θ.~~

~~30. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.8, 11.9, 15.1, 18.8, 19.2, 19.3, 22.0, 24.9, 25.1, 26.6 and 29.2 degrees 2θ.~~

~~31. The solid form of any one of claims 28-30, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 281 °C.~~

~~32. The solid form of any one of claims 28-31, having a thermal gravimetric analysis plot comprising a mass loss of less than about 0.1% when heated from about 25 °C to about 150 °C.~~

~~33. The solid form of any one of claims 28-32, which exhibits a mass increase of less than about 0.2% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.~~

~~34. The solid form of any one of claims 28-33, which is unsolvated.~~

~~35. The solid form of any one of claims 28-34, which is substantially nonhygroscopic.~~

~~36. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 10.~~

~~37. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 16.7, 21.7, 21.9 and 25.8 degrees 2θ.~~

~~38. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 10.6, 14.0, 14.6, 15.7, 16.3, 16.7, 18.8, 21.7, 21.9, 24.8, 25.1, 25.8, 28.1 and 28.6 degrees 2θ.~~

~~39. The solid form of any one of claims 36-38, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 283 °C.~~

~~40. The solid form of any one of claims 36-39, having a thermal gravimetric analysis plot comprising a mass loss of less than about 4% when heated from about 25 °C to about 150 °C.~~

41. The solid form of any one of claims 36-40, which exhibits a mass increase of less than or equal to about 6% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

42. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 13.

43. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 7.3, 14.6, 22.0, 30.0 and 37.0 degrees 2θ.

44. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 7.3, 9.3, 12.2, 14.0, 14.6, 15.7, 16.8, 21.0, 22.0, 22.7, 29.4, 30.0 and 37.0 degrees 2θ.

45. The solid form of any one of claims 42-44, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 279 °C.

46. The solid form of any one of claims 42-45, having a thermal gravimetric analysis plot comprising a mass loss of less than about 6% when heated from about 25 °C to about 150 °C.

47. The solid form of any one of claims 42-46, which exhibits a mass increase of less than about 0.5% when subjected to an increase in relative humidity from about 0% to about 95% relative humidity.

48. The solid form of any one of claims 42-47, which is hydrated.

49. The solid form of any one of claims 42-48, which is substantially nonhygroscopic.

50. The solid form of claim 1, having an X-ray powder diffraction pattern substantially as shown in FIG. 16.

51. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 14.5, 15.7, 22.7 and 29.9 degrees 2θ.

~~52. The solid form of claim 1, having an X-ray powder diffraction pattern comprising peaks at about 7.2, 9.1, 14.5, 15.7, 16.8, 18.3, 21.9, 22.7, 29.9 and 36.9 degrees 2θ.~~

~~53. The solid form of any one of claims 50-52, having a differential scanning calorimetry plot comprising an endothermic event with an onset temperature of about 267 °C.~~

~~54. The solid form of any one of claims 50-53, which is hydrated.~~

~~55. A mixture comprising two or more solid forms selected from the solid forms of any one of claims 1-54.~~

~~56~~11. A pharmaceutical composition comprising the solid form of any one of claims ~~1-54 or the mixture of claim 55~~1-10 and a pharmaceutical acceptable carrier, diluent or excipient.

~~57~~12. The pharmaceutical composition of claim ~~56~~11, wherein the composition is formulated for oral, parenteral, or intravenous administration.

~~58~~13. The pharmaceutical composition of claim ~~56~~-11 or ~~57~~12, wherein the composition is formulated as a single unit dosage form.

~~59~~14. The pharmaceutical composition of claim ~~58~~13, wherein the dosage form is a tablet or capsule.

~~60~~15. Use of a solid form of any one of claims 1 to ~~54~~10, ~~a mixture of claim 55,~~ or a composition of any one of claims ~~56~~-11 to ~~59~~-14 in the manufacture of a medicament for treating a disease or disorder, wherein the disease or disorder is selected from the group consisting of cancer, a disorder associated with angiogenesis, pain, macular degeneration or a related syndrome, a skin disease, a pulmonary disorder, an asbestos-related disorder, a parasitic disease, an immunodeficiency disorder, a CNS disorder, CNS injury, atherosclerosis or a related disorder, dysfunctional sleep or a related disorder, hemoglobinopathy or a related disorder, and a TNFα related disorder.

~~61~~16. The use of claim ~~60~~15, further comprising administering a second active agent.